What's in GBG Forschungs GmbH's pipeline?

GBG Forschungs GmbH has 18 drugs in our index: 2 marketed, 0 filed, 9 in Phase 3, 6 in Phase 2, 1 in Phase 1.

Which companies overlap with GBG Forschungs GmbH's portfolio?

Top competitors by shared drug class: AstraZeneca, Bayer, CTI BioPharma, Centre Leon Berard, Draig Therapeutics Ltd.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/gbg-forschungs-gmbh.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

GBG Forschungs GmbH — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GBG Forschungs GmbH pipeline: 2 marketed, 0 filed, 9 Phase 3, 6 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 9 Phase 3 6 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Ibandronat	Ibandronat	marketed			Other
NX	NX	marketed	Proton pump inhibitor	H+/K+ ATPase	Gastrointestinal
epirubicin - cyclophosphamide / docetaxel + bevacizumab	epirubicin - cyclophosphamide / docetaxel + bevacizumab	phase 3	anthracycline antibiotic, alkylating agent, taxane, monoclonal antibody	topoisomerase II, DNA, microtubules, VEGF	Oncology
Exemestane and GnRH analogue	Exemestane and GnRH analogue	phase 3	Aromatase inhibitor + GnRH agonist combination	Aromatase enzyme; GnRH receptor	Oncology
Ibandronate, Capecitabine	Ibandronate, Capecitabine	phase 3	Bisphosphonate + Fluoropyrimidine antimetabolite	Farnesyl pyrophosphate synthase (ibandronate); Thymidylate synthase (capecitabine)	Oncology
Palbociclib PD-0332991	Palbociclib PD-0332991	phase 3	CDK4/6 inhibitor	CDK4/6	Oncology
epirubicin - cyclophosphamide / docetaxel + lapatinib	epirubicin - cyclophosphamide / docetaxel + lapatinib	phase 3	anthracycline antibiotic, alkylating agent, taxane, tyrosine kinase inhibitor	topoisomerase II, DNA, microtubules, HER2, EGFR	Oncology
non-pegylated liposomal doxorubicin	non-pegylated liposomal doxorubicin	phase 3	anthracycline	topoisomerase II	Oncology
Tamoxifen and GnRH analogue	Tamoxifen and GnRH analogue	phase 3	Selective estrogen receptor modulator (SERM) and Gonadotropin-releasing hormone (GnRH) analogue	Estrogen receptor and GnRH receptor	Oncology
epirubicin - cyclophosphamide / docetaxel + trastuzumab	epirubicin - cyclophosphamide / docetaxel + trastuzumab	phase 3	anthracycline antibiotic/alkylating agent/taxane/monoclonal antibody	topoisomerase II/DNA/HER2/neu receptor	Oncology
Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa	Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa	phase 3	Chemotherapy combination with erythropoiesis-stimulating agent	DNA (epirubicin, cyclophosphamide), microtubules (paclitaxel), erythropoietin receptor (dabepoetin alfa)	Oncology

Therapeutic area mix

Oncology · 10
Gastrointestinal · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AstraZeneca · 1 shared drug class
Bayer · 1 shared drug class
CTI BioPharma · 1 shared drug class
Centre Leon Berard · 1 shared drug class
Draig Therapeutics Ltd · 1 shared drug class
Fujian Cancer Hospital · 1 shared drug class
GERCOR - Multidisciplinary Oncology Cooperative Group · 1 shared drug class
AVM Biotechnology Inc · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for GBG Forschungs GmbH:

Cite this brief

Drug Landscape (2026). GBG Forschungs GmbH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/gbg-forschungs-gmbh. Accessed 2026-05-16.